comparemela.com

Latest Breaking News On - Nick rigopulos - Page 14 : comparemela.com

XORTX Receives No Objection Letter from Health Canada

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

United statesNick rigopulosAllen davidoffExchange commissionTherapeutics incDrug administrationEuropean medicines agencyHealth canadaVenture exchangeAutosomal dominant polycystic kidney diseaseNew drug applicationUnited states foodEuropean medicinesAnnual information formManagement discussionCovid 19

XORTX Provides Corporate Update | MarketScreener

CALGARY, Alberta, Jan. 31, 2022 XORTX Therapeutics Inc. , a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, is pleased to. | January 31, 2022

United statesRaymond prattNick rigopulosAllen davidoffCharles edelsteinJacqueline le sauxStephen haworthAmar keshriBill farleyBusiness development at chemdivEuropean patent officeWuxi apptec incAmerican society of nephrology advisory committee memberTherapeutics incEuropean unionCanadian securities exchange

XORTX Provides Corporate Updat - GuruFocus com

GuruFocus Article or News written by GuruFocusNews and the topic is about:

United statesRaymond prattNick rigopulosAllen davidoffCharles edelsteinJacqueline le sauxStephen haworthAmar keshriBill farleyBusiness development at chemdivEuropean patent officeWuxi apptec incAmerican society of nephrology advisory committee memberTherapeutics incEuropean unionVenture exchange

XORTX Announces Appointment of Chief Technology Officer

CALGARY, Alberta, Jan. 20, 2022 (GLOBE NEWSWIRE) XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a.

Nick rigopulosAllen davidoffUniversity of albertaTherapeutics incMethylation sciences incDavid macdonaldChief technology officerActive passAutosomal dominant polycystic kidney diseaseTsx venture exchange xrtxOrtx therapeutics inc

XORTX Announces Appointment of Chief Technology Officer

20.01.2022 - CALGARY, Alberta, Jan. 20, 2022 (GLOBE NEWSWIRE) - XORTX Therapeutics Inc. ( XORTX or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical therapeutics company focused on developing innovative therapies to treat .

Nick rigopulosAllen davidoffUniversity of albertaTherapeutics incMethylation sciences incActive passAutosomal dominant polycystic kidney disease

vimarsana © 2020. All Rights Reserved.